12 Biggest Mid-Day Gainers For Monday

Array Biopharma Inc ARRY shares jumped 57.9 percent to $5.76 after the company disclosed that its COLUMBUS Phase 3 study of encorafenib plus binimetinib for BRAF-mutant melanoma has met primary endpoint.
Lipocine Inc LPCN shares climbed 23.4 percent to $4.80 after the company reported positive top-line Phase 2b study results for LPCN 1111.
Chemtura Corp CHMT shares surged 15.8 percent to $32.63 as LANXESS AG NPV LNXSF announced Sunday, it has signed a contract to acquire the company for $33.50 per share in cash or $2.5 billion.
Actua Corp ACTA shares surged 15 percent to $ 11.81. Actua reported a deal to sell GovDelivery to an investor group led by Vista Equity Partners for $153 million in cash.
GW Pharmaceuticals PLC- ADR GWPH climbed 14.2 percent to $122.82 as the company revealed Epidiolex has achieved primary endpoint in treating Lennox-Gastaut syndrome. The positive results came from its randomized, double-blind and placebo-controlled final stage clinical study.
Summit Therapeutics PLC (ADR) SMMT climbed 14.1 percent to $10.03 as the company disclosed that it has received Fast Track designation from the FDA for ezutromid in the treatment of DMD.
Real Goods Solar, Inc. RGSE shares gained 14.1 percent to $2.28. Real Goods Solar shares have tumbled 91.87 percent over the past 52 weeks, while the S&P 500 index has gained 15.03 percent in the same period.
Zynerba Pharmaceuticals Inc ZYNE shares rose 8.2 percent to $13.69. Jefferies reiterated Buy rating and $32 price target on Zynerba Pharmaceuticals.
Aldeyra Therapeutics Inc ALDX shares climbed 7.3 percent to $8.00. H.C. Wainwright initiated coverage on Aldeyra Therapeutics with a Buy rating.
Diebold Inc DBD gained 6.4 percent to $26.04. JP Morgan upgraded Diebold from Neutral to Overweight.
Columbia Pipeline Partners LP CPPL gained 6.4 percent to $16.28. TransCanada Corporation (USA) TRP offered to buy Columbia Pipeline Partners for $15.75 per share.
Exelixis, Inc. EXEL rose 2.5 percent to $15.26 as the company disclosed that it has received a $15 million milestone payment for initiation of Phase 3 study for CS-3150.